Geron Corporation (NASDAQ: GERN) saw its stock price soar by 6.82% in pre-market trading on Wednesday following the release of its first-quarter 2025 financial results. The biopharmaceutical company, focused on developing treatments for hematologic malignancies, reported better-than-expected earnings per share (EPS) and operating income, despite missing revenue estimates.
According to the company's report, Geron posted a quarterly EPS of -$0.03, surpassing the analyst consensus estimate of -$0.04 by 25%. This represents a significant improvement from the -$0.09 per share loss reported in the same period last year. The company's operating income came in at -$16.704 million, outperforming the estimated -$23.5 million loss projected by analysts.
While Geron's quarterly sales of $39.60 million fell short of the $48.22 million analyst estimate, it still marked a substantial increase from the $304,000 reported in the same quarter of the previous year. This growth in revenue, coupled with the better-than-expected bottom-line results, appears to have bolstered investor confidence in the company's financial health and operational efficiency, driving the stock's positive movement in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.